Research Grid Showcases AI Efficiency Gains in Cardiac Imaging Trial

According to a recent LinkedIn post from Research Grid, the company is highlighting a real-world deployment of its AI platform in a large cardiac imaging trial involving more than 600 patients at Queen Mary University of London and Barts Health NHS Trust. The post describes the collaboration as an example of how academic, healthcare and SME partnerships can move beyond transactional interactions toward operational outcomes.

The LinkedIn post indicates that Research Grid’s AI was used to automate one of the most labor-intensive components of the study: data entry from thousands of pages of patient records, including handwritten notes, scanned documents and structured data. According to the post, the system digitized and processed records in seconds or minutes, incorporating quality checks and anonymization.

The post suggests that in this deployment, potential efficiencies included an estimated $1.5 million in savings on data entry and automation of more than 24,000 staff hours, while processing over 600 patient records rapidly. It also asserts that data quality could be “exceptional” with human errors eliminated, positioning the use case as a demonstration of AI in a live clinical environment with real patient data.

For investors, the example may signal that Research Grid’s technology is moving from proof-of-concept to practical implementation in complex clinical workflows, which could strengthen its value proposition to hospitals, academic centers and contract research organizations. If these reported efficiency gains prove repeatable at scale, they could support a recurring revenue model tied to research operations and potentially improve margins for customers.

The post further notes that the results point to broader opportunities for purpose-built automation to address structural inefficiencies in research operations, particularly where skilled staff are engaged in repetitive administrative tasks. This focus on implementation and scaling of “traceable models” could help differentiate Research Grid within the clinical research technology segment, where regulators and sponsors increasingly scrutinize data integrity and auditability.

More broadly, the highlighted collaboration may enhance Research Grid’s positioning within the U.K. and European clinical research ecosystem, potentially opening doors to additional partnerships or pilots. While the post does not disclose commercial terms, sustained adoption in similar trials could increase the company’s visibility in the clinical AI market and support long-term growth prospects if converted into contracted deployments.